Critical

Rapidly progressive glomerulonephritis (RPGN; crescentic glomerulonephritis)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A clinical-pathological syndrome, not a single disease: nephritic presentation with loss of renal function over days-weeks and crescents in >50% of glomeruli on biopsy. Three immunopathological groups: (1) pauci-immune/ANCA-associated (commonest — GPA/MPA/EGPA), (2) anti-GBM disease, (3) immune-complex (lupus, IgA/IgA vasculitis, post-infectious, MPGN, cryoglobulinaemia). A medical emergency where rapid biopsy + serology and empirical immunosuppression preserve kidney function — treat first, the window is short.

Red flags

  • Creatinine doubling over days to a week with active sediment — treat now, biopsy urgently
  • Pulmonary haemorrhage/haemoptysis with hypoxia — pulmonary-renal syndrome, ITU
  • Oligo-anuria / dialysis requirement at presentation — narrowing window for renal recovery
  • Multisystem features (rash, sinus/ENT, neuropathy, haemoptysis) — systemic vasculitis
  • Delay to biopsy/serology — the main modifiable cause of lost kidneys

Assessment

Differential diagnosis

  • ANCA-associated vasculitis (MPO/PR3) — pauci-immune RPGN
  • Anti-GBM disease (linear IgG, pulmonary-renal syndrome)
  • Immune-complex: lupus nephritis, IgA/IgA vasculitis, post-infectious GN, MPGN, cryoglobulinaemia (often with endocarditis/hepatitis C)
  • Thrombotic microangiopathy (HUS/TTP/malignant hypertension/scleroderma renal crisis) mimicking rapid GFR loss
  • Acute tubular necrosis / acute interstitial nephritis (bland or non-nephritic sediment)

Investigations

  • URGENT serology ('renal emergency screen'): ANCA (MPO/PR3), anti-GBM, ANA/dsDNA, complement C3/C4, cryoglobulins, hepatitis B/C, ASOT
  • Urine microscopy (dysmorphic RBCs + red cell/cellular casts — the nephritic hallmark), PCR/ACR
  • U&E/creatinine/eGFR with trend (rapid rise), FBC, CRP/ESR, blood cultures (endocarditis)
  • CXR/CT chest for pulmonary haemorrhage; ENT/sinus and nerve assessment if vasculitis
  • URGENT renal biopsy — crescents; immunofluorescence pattern (pauci-immune vs linear IgG vs granular immune-complex) classifies the cause and directs therapy
  • Pre-immunosuppression screen: HBV/HCV/HIV, TB, pregnancy test, baseline FBC/LFTs

Management

  • Recognise the syndrome early (rising creatinine + active nephritic sediment) and escalate immediately — send the renal emergency serology screen and arrange urgent biopsy
  • Start empirical high-dose corticosteroids (pulse IV methylprednisolone) when RPGN is strongly suspected and the patient is deteriorating, before definitive results, in discussion with nephrology
  • Direct definitive therapy by cause once biopsy/serology known:
  • - ANCA-associated: induction with glucocorticoids + rituximab (or cyclophosphamide); add plasma exchange for severe renal failure/dialysis-dependence or pulmonary haemorrhage (per PEXIVAS-informed selective use)
  • - Anti-GBM: urgent plasma exchange + steroids + cyclophosphamide (treat before dialysis dependence)
  • - Immune-complex (lupus/IgA/post-infectious/cryo): treat the underlying disease (e.g. lupus induction, treat infection/HCV, crescentic IgA steroids +/- cyclophosphamide)
  • Supportive care: manage AKI complications (hyperkalaemia, acidosis, overload), RRT for standard indications, treat/ventilate pulmonary haemorrhage
  • Infection prophylaxis (PCP) and monitoring for immunosuppression toxicity; plan maintenance immunosuppression (especially ANCA/lupus) to prevent relapse

Drugs & doses

Methylprednisolone 500 mg-1 g IV once daily x3 days then oral prednisolone ~1 mg/kg/day (max ~60-80 mg) tapering (reduced-dose taper per PEXIVAS in ANCA) [verify local dose]
Rituximab 375 mg/m2 weekly x4 OR 1 g x2 (ANCA induction) [verify local dose]
Cyclophosphamide IV pulsed (~15 mg/kg, age/renal-adjusted) or oral 2 mg/kg/day (ANCA or anti-GBM induction) [verify local dose]
Plasma exchange for anti-GBM, and for severe/dialysis-dependent ANCA renal disease or pulmonary haemorrhage [verify local protocol]
Disease-specific therapy for immune-complex RPGN (lupus induction, treat underlying infection/HCV cryoglobulinaemia) [verify local dose]
Co-trimoxazole PCP prophylaxis; hyperkalaemia/acidosis bundle and RRT as required [verify local dose]

Disposition

Emergency admission under nephrology (HDU/ITU if pulmonary haemorrhage or severe AKI). Requires same-day serology + biopsy and prompt immunosuppression. Long-term maintenance immunosuppression and relapse monitoring for ANCA/lupus causes.

Complications & pitfalls

  • Irreversible ESKD if treatment delayed
  • Life-threatening pulmonary haemorrhage
  • Immunosuppression toxicity: infection, cyclophosphamide/rituximab adverse effects
  • Disease relapse (particularly ANCA vasculitis)
  • Complications of severe AKI (hyperkalaemia, acidosis, overload)

Exam pearls

  • RPGN is defined by the CLINICAL tempo (fast GFR loss + nephritic sediment) and confirmed by CRESCENTS on biopsy — think of it as a syndrome with three serological buckets: pauci-immune (ANCA), linear (anti-GBM) and granular (immune-complex).
  • Send the 'renal emergency screen' (ANCA, anti-GBM, ANA/dsDNA, complement, cryoglobulins, hepatitis serology) and get an urgent biopsy the same day — empirical pulse steroids can start before results in a deteriorating patient.
  • Plasma exchange is standard for anti-GBM and is used selectively (severe renal failure/dialysis dependence or pulmonary haemorrhage) in ANCA disease following PEXIVAS.
  • The commonest single cause is ANCA-associated vasculitis; always look for the other organs (lungs, ENT, skin, nerves).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.